Work that began at OMRF in the 1980s gives birth to a life-changing medication When Novartis announced in November that the U.S. Food and Drug Administration had approved the company’s new drug to treat sickle cell anemia, the press release didn’t mention Oklahoma. But it should have. The drug, known as Adakveo, is based […]
Adakveo significantly reduces pain crises in sickle cell patients.
Scientists at OMRF have made new findings that could pave the way for the first drug to treat aortic stenosis.
The scholars were selected from a pool of 70 applicants from across the state.
High school seniors, as well as college freshmen, sophomores and juniors, are eligible to apply.
For Mary Long, the answer to her pain may, literally, be right around the corner.